Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Mass Companies with QTDP Grants

A  number of Massachusetts biotechnology companies have received grants as part of the Qualifying Therapeutic Discovery Project, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010

It provides a tax credit or grant equal to eligible costs and expenses for tax years 2009 and 2010.  Therapeutic Discovery Tax Credit program that was established within the federal health reform law approved in March.

  • Each grant, which is designed to offset up to 50% of qualifying research and development costs is worth $244,479.24 and companies are eligible for more than 1 award. Companies must have headcount under 250, and companies meeting significant unmet medical needs will have priority. Medical device companies, as well as biotechs are eligible. The total amount of grant money available nationwide is $1B.

The biggest winners: Alnylam Pharmaceuticals, which won 8 grants worth a total of $1,955,832. Celldex was awarded 7 grants worth $1,711,353 in all. ImmunoGen won 5 grants worth a total of $1,222,396.20. Momenta Pharmaceuticals, RXi Pharmaceuticals, ArQule and Advanced Cell Technology each won 4 grants worth a total of $977,917. (HWM and J M Donnelly, BBJ)

A number of biotechs include:

  • Quanterix Corporation,
  • BIND Biosciences,
  • Tolerx,
  • Ensemble Therapeutics,
  • Tetraphase Pharmaceuticals
  • Selecta Biosciences,
  • Bluebird bio
  • Concert Pharmaceuticals;
  • Avila Therapeutics,
  • Pro-Pharmaceuticals,
  • Zalicus,
  • Taligen Therapeutics,
  • Constellation Pharmaceuticals,
  • Hydra Biosciences,
  • Semprus Biosciences;
  • NormOxys,
  • Pulmatrix, ,`
  • X-BODY BioSciences,
  • Pressure Biosciences